TRIM33 and dermatomyositis: Dysphagia is common in anti-TIF1-γ-positive DM,[16–18] and early consideration of enteral nutrition is advisable.[19] Inflammatory cell infiltration and muscle atrophy have been observed in pathological studies, and the treatment typically includes pharmacotherapy, swallowing rehabilitation, and sometimes surgery.